Thyssen, Jacob P.
Buhl, Timo
Fernández-Peñas, Pablo
Kabashima, Kenji
Chen, Sherry
Lu, Na
DeLozier, Amy M.
Casillas, Marta
Ständer, Sonja
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
https://doi.org/10.1007/s13555-022-00828-5
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
https://doi.org/10.1007/s13555-021-00577-x
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
https://doi.org/10.1007/s40257-021-00602-x
Documents that mention this clinical trial
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
https://doi.org/10.1007/s13555-022-00828-5
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
https://doi.org/10.1007/s13555-021-00577-x
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
https://doi.org/10.1007/s40257-021-00602-x
Documents that mention this clinical trial
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
https://doi.org/10.1007/s13555-022-00828-5
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
https://doi.org/10.1007/s13555-021-00577-x
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
https://doi.org/10.1007/s40257-021-00602-x
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 8 April 2021
First Online: 18 July 2021